Blog

As IBA Lifesciences’ U.S. distributor, Neuromics is proud to provide our customers with the most advanced tools for protein purification. Through the end of the year, you can now save 5% on IBA’s premier resin - Strep-Tactin® 4Flow® High Capacity - a trusted choice for achieving high yield and purity.

Strep-Tactin® 4Flow® High Capacity represents the latest generation of IBA’s purification technology. The resin features a low-concentration (4%) and pressure-stable agarose coupled with a high Strep-Tactin® density, resulting in:

• Exceptional protein binding capacity
• Compatibility with FPLC workstations
• High yields across all protein classes, including large and complex proteins
• Superior stability supporting at least 50 regeneration cycles

Image: The increased density of Strep-Tactin® molecules immobilized on Strep-Tactin® 4Flow® high capacity translates to an overall high binding capacity compared to Strep-Tactin® Sepharose® and Strep Tactin® Superflow® high capacity.

If you're using human cell-based assays to research neurodegenerative diseases, your work demands consistent and reliable human neural cells. Neuromics has you covered, with an impressive history of customers using our human cells to study neurodegenerative diseases.

Some examples from the past few years:

• Our primary human neurons (cat. HNC001) linked long COVID to Alzheimer's disease (AD) (check it out).
• The mechanisms connecting periodontitis and AD were explored with our 3D human blood-brain barrier model (cat. 3D45002) (learn more).
• Researchers explored how Semaphorin 4D expression leads to neurodegenerative diseases in our human brain astrocytes (cat. HMP202) (read more).

Image: Neuromics Human Brain Microvascular Endothelial Cells (cat. HEC02) stained with CD146.

Then, just last week, scientists from Imperial College in London used our primary human brain microvascular endothelial cells (HBMECs) (cat. HEC02) in an AD study.

Neuromics is pleased to announce the release of five new human cell types for research in diabetes and obesity. This introduction builds on an existing inventory of human cells, specifically endothelial cells, which have a long history of being utilized to study diabetes and obesity (learn more).

Our new selection offers unique opportunities for disease-specific models, as we've chosen Adipose-Derived Stem Cells (ADSCs), fibroblasts, and hepatic stellate cells isolated from diseased donors. The cells are suited for any researcher studying type 1 diabetes, type 2 diabetes, obesity, or non-alcoholic steatohepatitis (NASH).

Image: Formation of tube networks in Neuromics HRMECs in normal glucose (NG) and high glucose (HG) conditions.

Here are the new cell types:

• ADSCs - Obesity Donor (cat. ADSC001)
• ADSCs - Type 1 Diabetes Donor (cat. ADSC002)
• ADSCs - Type 2 Diabetes Donor (cat. ADSC003)
• Dermal Fibroblasts - Type 1 Diabetes Donor (cat. HDF002)
• Hepatic Stellate Cells - NASH Donor (cat. HHSC001)

With colorectal cancer (CRC) being one of the most prevalent cancers worldwide, understanding chemotherapy resistance in the CRC tumor microenvironment (TME) is an important goal. As we’ve seen in many other publications using our human cancer-associated fibroblasts (CAFs), CAFs play a huge role in the TME.

Our CAFs have been used in a handful of studies in 2D and 3D TME models, where they demonstrate their ability to complicate treatment objectives. Overall, the mechanisms by which CAFs contribute to chemotherapy resistance in the TME are poorly understood. 

Image: DKK1 expression in Neuromics colorectal CAFs when subjected to chemotherapeutic agents.

Researchers from the University of Kentucky utilized our colorectal CAFs (cat. CAF115) in a new paper examining these mechanisms. In their cell models, they found that CAFs secrete DKK1, a protein associated with tumor growth and metastasis, when subjected to chemotherapy treatments for CRC. Their results identified CAF-secreted DKK1 as a major player in resistance to treatment. Furthermore, they recommend looking into treatments that target DKK1 to counteract chemotherapy resistance.

You can check out the full paper here.

When researchers employ our human primary cancer associated fibroblasts (CAFs) in their tumor microenvironment models, they consistently find stark differences between 2D and 3D. Through 3D co-culture, investigators recognize that their models mirror in vivo tumors more closely than in 2D.

This makes our CAFs invaluable, enabling drug discovery research that better mimics the tumor microenvironment. Furthermore, over the last few years, we've seen the observation across many of our CAF types, including pancreatic, colorectal, breast, and now, ovarian.

Image: Human ovarian cancer cell lines (SKOV3 and OVACR8) along with Neuromics ovarian CAFs (cat. CAF112) in 2D and 3D ovarian cancer models.